

REMARKS

The claims have been amended to limit the claims to a drug composition comprising PC-SOD and sucrose.

The 35 U.S.C. 112, second paragraph rejection has been rendered moot by deletion of the terminology which the Examiner found objectionable.

The 35 U.S.C. 103(a) rejections based on JP 9-117279 in view of JP-304882 and on the same combination in further view of Kinoshita et al. are respectfully traversed for the following reasons.

JP 9-117279 discloses a drug composition comprising PC-SOD but not sucrose.

JP 1-304882 discloses a drug composition comprising Zn/Cu SOD and sucrose but not PC-SOD.


Kinoshita has been cited relative to only method claims which have now been canceled.

The Examiner has not shown that it would have been obvious to formulate applicants' PC-SOD composition with sucrose. The mere fact that Zn/Cu SOD has been so formulated does not suggest adding sucrose to PC-SOD of JP 9-117279.

Respectfully submitted,

JORDAN AND HAMBURG LLP

By



C. Bruce Hamburg

Reg. No. 22,389

Attorney for Applicants

Jordan and Hamburg LLP
122 East 42nd Street
New York, New York 10168
(212) 986-2340